Fig. 7
IKNM Movements Are Inhibited when MyosinII Activity Is Blocked, but the Effect Can be Rescued by MRLC2T18DS19D (A) Images from Movies S13–S15 at 3 hr intervals. Pseudocolored nuclei in WT (upper panel) travel further than nuclei treated with 100 μM Blebbistatin or 25 mM BDM (lower panels). Arrows mark a mitotic but not separated nucleus in BDM treatment. (B) Stochastic motion velocity distributions for Blebbistatin- and BDM-treated embryos, and centrin morphants and DNp150-expressing cells treated with BDM. (C) Stochastic motion MSD profiles (error bars show 95% confidence intervals) with linear fit for Blebbistatin- and BDM-treated embryos, and centrin morphant and DNp150-expressing cells treated with BDM. (D) Stochastic motion velocity distributions for BDM-treated embryos injected with MRLC2T18DS19D-GFP or wild-type MRLC2-GFP, respectively. (E) Stochastic motion MSD profiles (error bars show 95% confidence intervals) with linear fit for BDM-treated embryos injected with MRLC2T18DS19D-GFP or MRLC2-GFP, respectively. Only the activated MRLC partially rescues the effect of BDM treatment. Scale bars represent 10 μm. |
| Fish: | |
|---|---|
| Condition: | |
| Observed In: | |
| Stage: | Prim-5 |
Reprinted from Cell, 138(6), Norden, C., Young, S., Link, B.A., and Harris, W.A., Actomyosin is the main driver of interkinetic nuclear migration in the retina, 1195-1208, Copyright (2009) with permission from Elsevier. Full text @ Cell